Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
37 hedge funds and large institutions have $233M invested in Sierra Oncology, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
38% more capital invested
Capital invested by funds: $169M → $233M (+$63.9M)
9% more funds holding
Funds holding: 34 → 37 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$12M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.11M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.59M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$1.56M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.3M |
| 3 |
TI
Telemetry Investments
New York
|
-$241K |
| 4 |
Millennium Management
New York
|
-$160K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$139K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BlackRock
New York
| $448K | -$20.6K | -1,031 | -5% |
|
27
Geode Capital Management
Boston,
Massachusetts
| $220K | +$202K | +10,075 | New |
|
|
JSC
28
Jackson Square Capital
San Francisco,
California
| $201K | +$183K | +9,152 | New |
|
|
S
29
SignatureFD
Atlanta,
Georgia
| $55K | – | – | – |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $47K | – | – | – |
|
31
Wells Fargo
San Francisco,
California
| $26K | – | – | – |
|
32
Osaic Holdings
Scottsdale,
Arizona
| $19K | +$1.82K | +91 | +12% |
|
33
Group One Trading
Chicago,
Illinois
| $5K | – | – | – |
|
34
JP Morgan Chase
New York
| $2K | +$2K | +100 | New |
|
35
Morgan Stanley
New York
| $1K | +$460 | +23 | +230% |
|
|
OSAM
36
O'Shaughnessy Asset Management
Stamford,
Connecticut
| $1K | +$820 | +41 | New |
|
|
RE
37
RBC Europe
London,
United Kingdom
| $526 | – | – | – |
|
|
PA
38
Perceptive Advisors
New York
| – | -$1.3M | -66,655 | Closed |
|
|
TI
39
Telemetry Investments
New York
| – | -$241K | -12,349 | Closed |
|
|
SB
40
Strategic Blueprint
Atlanta,
Georgia
| – | -$15K | -782 | Closed |
|
SRRA Hedge Fund Activity: Q3 2021 in Review
37 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2021, worth a combined $233M — up 38% from $169M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SRRA positions and 3 closed out — a net gain of 4 holders — while 13 added to existing stakes and 7 trimmed.
The largest buyer was Frazier Management, adding an estimated $12M. The largest seller was Nan Fung Group Holdings, cutting an estimated $1.56M.
- 37 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2021, up from 34 in Q2 2021.
- Funds reported $233M of Sierra Oncology, Inc. Common Stock stock for Q3 2021, up 38% quarter-over-quarter.
- 7 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +4 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2021 was Frazier Management, an estimated $12M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q3 2021 was Nan Fung Group Holdings, an estimated $1.56M sold.
Based on aggregated 13F filings for Q3 2021.